These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 21467160)

  • 41. Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas.
    Chung CH; Ely K; McGavran L; Varella-Garcia M; Parker J; Parker N; Jarrett C; Carter J; Murphy BA; Netterville J; Burkey BB; Sinard R; Cmelak A; Levy S; Yarbrough WG; Slebos RJ; Hirsch FR
    J Clin Oncol; 2006 Sep; 24(25):4170-6. PubMed ID: 16943533
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Generation and molecular characterization of head and neck squamous cell lines of fanconi anemia patients.
    van Zeeburg HJ; Snijders PJ; Pals G; Hermsen MA; Rooimans MA; Bagby G; Soulier J; Gluckman E; Wennerberg J; Leemans CR; Joenje H; Brakenhoff RH
    Cancer Res; 2005 Feb; 65(4):1271-6. PubMed ID: 15735012
    [TBL] [Abstract][Full Text] [Related]  

  • 43. TP53 mutation, allelism and survival in non-small cell lung cancer.
    Nelson HH; Wilkojmen M; Marsit CJ; Kelsey KT
    Carcinogenesis; 2005 Oct; 26(10):1770-3. PubMed ID: 15905205
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The role of HPV RNA transcription, immune response-related gene expression and disruptive TP53 mutations in diagnostic and prognostic profiling of head and neck cancer.
    Wichmann G; Rosolowski M; Krohn K; Kreuz M; Boehm A; Reiche A; Scharrer U; Halama D; Bertolini J; Bauer U; Holzinger D; Pawlita M; Hess J; Engel C; Hasenclever D; Scholz M; Ahnert P; Kirsten H; Hemprich A; Wittekind C; Herbarth O; Horn F; Dietz A; Loeffler M;
    Int J Cancer; 2015 Dec; 137(12):2846-57. PubMed ID: 26095926
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Impact of KRAS and TP53 mutations on survival in patients with left- and right-sided Dukes' C colon cancer.
    Bleeker WA; Hayes VM; Karrenbeld A; Hofstra RM; Hermans J; Buys CC; Plukker JT
    Am J Gastroenterol; 2000 Oct; 95(10):2953-7. PubMed ID: 11051374
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Combined vascular endothelial growth factor and TP53 status predicts poor response to tamoxifen therapy in estrogen receptor-positive advanced breast cancer.
    Berns EM; Klijn JG; Look MP; Grebenchtchikov N; Vossen R; Peters H; Geurts-Moespot A; Portengen H; van Staveren IL; Meijer-van Gelder ME; Bakker B; Sweep FC; Foekens JA
    Clin Cancer Res; 2003 Apr; 9(4):1253-8. PubMed ID: 12684392
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A novel nuclear factor-kappaB gene signature is differentially expressed in head and neck squamous cell carcinomas in association with TP53 status.
    Lee TL; Yang XP; Yan B; Friedman J; Duggal P; Bagain L; Dong G; Yeh NT; Wang J; Zhou J; Elkahloun A; Van Waes C; Chen Z
    Clin Cancer Res; 2007 Oct; 13(19):5680-91. PubMed ID: 17908957
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prediction of TP53 status for primary cisplatin, fluorouracil, and leucovorin chemotherapy in ethmoid sinus intestinal-type adenocarcinoma.
    Licitra L; Suardi S; Bossi P; Locati LD; Mariani L; Quattrone P; Lo Vullo S; Oggionni M; Olmi P; Cantù G; Pierotti MA; Pilotti S
    J Clin Oncol; 2004 Dec; 22(24):4901-6. PubMed ID: 15611505
    [TBL] [Abstract][Full Text] [Related]  

  • 49. FGFR4 polymorphism, TP53 mutation, and their combinations are prognostic factors for oral squamous cell carcinoma.
    Tanuma J; Izumo T; Hirano M; Oyazato Y; Hori F; Umemura E; Shisa H; Hiai H; Kitano M
    Oncol Rep; 2010 Mar; 23(3):739-44. PubMed ID: 20127014
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Homozygous deletions of UGT2B17 modifies effects of smoking on TP53-mutations and relapse of head and neck carcinoma.
    Mafune A; Hama T; Suda T; Suzuki Y; Ikegami M; Sakanashi C; Imai S; Nakashima A; Yokoo T; Wada K; Kojima H; Urashima M
    BMC Cancer; 2015 Mar; 15():205. PubMed ID: 25886176
    [TBL] [Abstract][Full Text] [Related]  

  • 51. TP53 mutation is related to poor prognosis after radiotherapy, but not surgery, in squamous cell carcinoma of the head and neck.
    Alsner J; Sørensen SB; Overgaard J
    Radiother Oncol; 2001 May; 59(2):179-85. PubMed ID: 11325447
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Expression of SESN1, UHRF1BP1, and miR-377-3p as prognostic markers in mutated TP53 squamous cell carcinoma of the head and neck.
    El Baroudi M; Machiels JP; Schmitz S
    Cancer Biol Ther; 2017 Oct; 18(10):775-782. PubMed ID: 28886272
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Specific TP53 mutations predict aggressive phenotype in head and neck squamous cell carcinoma: a retrospective archival study.
    Peltonen JK; Vähäkangas KH; Helppi HM; Bloigu R; Pääkkö P; Turpeenniemi-Hujanen T
    Head Neck Oncol; 2011 Apr; 3():20. PubMed ID: 21513535
    [TBL] [Abstract][Full Text] [Related]  

  • 54. p53 mutation and locoregional treatment failure in head and neck squamous cell carcinoma.
    Koch WM; Brennan JA; Zahurak M; Goodman SN; Westra WH; Schwab D; Yoo GH; Lee DJ; Forastiere AA; Sidransky D
    J Natl Cancer Inst; 1996 Nov; 88(21):1580-6. PubMed ID: 8901856
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Analysis of mutations within the TP53 gene in patients with squamous cell carcinoma of the head and neck].
    Golusinski P; Lamperska K; Pazdrowski J; Golusinski W
    Otolaryngol Pol; 2011; 65(2):114-21. PubMed ID: 21735667
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Expression of TP53 mutation-associated microRNAs predicts clinical outcome in head and neck squamous cell carcinoma patients.
    Ganci F; Sacconi A; Bossel Ben-Moshe N; Manciocco V; Sperduti I; Strigari L; Covello R; Benevolo M; Pescarmona E; Domany E; Muti P; Strano S; Spriano G; Fontemaggi G; Blandino G
    Ann Oncol; 2013 Dec; 24(12):3082-8. PubMed ID: 24107801
    [TBL] [Abstract][Full Text] [Related]  

  • 57. TP53 disruptive mutations lead to head and neck cancer treatment failure through inhibition of radiation-induced senescence.
    Skinner HD; Sandulache VC; Ow TJ; Meyn RE; Yordy JS; Beadle BM; Fitzgerald AL; Giri U; Ang KK; Myers JN
    Clin Cancer Res; 2012 Jan; 18(1):290-300. PubMed ID: 22090360
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Computational analysis of TP53 mutational landscape unveils key prognostic signatures and distinct pathobiological pathways in head and neck squamous cell cancer.
    Caponio VCA; Troiano G; Adipietro I; Zhurakivska K; Arena C; Mangieri D; Mascitti M; Cirillo N; Lo Muzio L
    Br J Cancer; 2020 Oct; 123(8):1302-1314. PubMed ID: 32684626
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Allelic expression imbalance of TP53 mutated and polymorphic alleles in head and neck tumors.
    Ganci F; Conti S; Fontemaggi G; Manciocco V; Donzelli S; Covello R; Muti P; Strano S; Blandino G; Spriano G
    OMICS; 2011 Jun; 15(6):375-81. PubMed ID: 21348641
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Disruptive TP53 mutation is associated with aggressive disease characteristics in an orthotopic murine model of oral tongue cancer.
    Sano D; Xie TX; Ow TJ; Zhao M; Pickering CR; Zhou G; Sandulache VC; Wheeler DA; Gibbs RA; Caulin C; Myers JN
    Clin Cancer Res; 2011 Nov; 17(21):6658-70. PubMed ID: 21903770
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.